MyFinsight
Home
Blog
About
Proceeds from maturities
and sales of...
$26,000K
(-75.31%↓ Y/Y)
Net cash provided by
investing activities
$26,000K
(-61.29%↓ Y/Y)
Net change in cash
and cash...
$7,647K
(546.41%↑ Y/Y)
Canceled cashflow
$18,353K
Accounts payable
$11,778K
(432.24%↑ Y/Y)
Stock-based compensation
expense
$2,524K
(-49.24%↓ Y/Y)
Accrued expenses and
other liabilities
$2,504K
(-49.54%↓ Y/Y)
Noncash interest
expense
$362K
(-40.95%↓ Y/Y)
Change in fair value of
embedded derivatives
-$160K
(-206.67%↓ Y/Y)
Amortization of right-of-use
asset
$34K
(-44.26%↓ Y/Y)
Depreciation
$11K
(-64.52%↓ Y/Y)
Proceeds from exercise of
stock options
$27K
(-27.03%↓ Y/Y)
Net cash used in
operating activities
-$18,075K
(72.59%↑ Y/Y)
Net cash provided by
(used in) financing...
-$278K
(-672.22%↓ Y/Y)
Canceled cashflow
$17,373K
Canceled cashflow
$27K
Net loss
-$32,718K
(53.09%↑ Y/Y)
Proceeds from private
placement, net of offering...
-$305K
Accrued clinical trial
expenses
-$1,920K
(54.67%↑ Y/Y)
Prepaid expenses and
other current assets
$620K
(136.17%↑ Y/Y)
Amortization of premiums and
accretion of discounts on...
$186K
(-71.12%↓ Y/Y)
Other long-term
assets
$4K
(122.22%↑ Y/Y)
Back
Back
Cash Flow
Acumen Pharmaceuticals, Inc. (ABOS)
Acumen Pharmaceuticals, Inc. (ABOS)
source: myfinsight.com